Investment Rating - The investment rating for the company is "Outperform the Market" (maintained) [1][18] Core Views - The company is advancing its innovative drug clinical trials rapidly, maintaining steady growth in performance, and currently has a low valuation with stable dividends. Due to the core product sales growth exceeding expectations, the profit forecast has been raised, with projected net profits for 2024-2026 being 2.017 billion, 2.296 billion, and 2.571 billion yuan respectively, representing year-on-year growth of 30.2%, 13.8%, and 12.0% [2][18]. Summary by Sections Strategic Cooperation - The company has reached a strategic cooperation with Bai Li Tian Heng to jointly promote the combined treatment of 707 and BL-B01D1 for solid tumors in China [2]. Product Development - 707 is a PD-1xVEGF dual antibody developed by the company, with advanced research progress and excellent early clinical data, expected to enter Phase III clinical trials in the second half of this year [2][18]. - The core product, Teibiao, continues to see sales growth and has achieved favorable results in medical insurance negotiations, expected to maintain steady growth in 2025-2026 [2][18]. Clinical Data - 707 has shown good clinical data in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), with over 300 patients enrolled in clinical trials [5][9]. - In a Phase II clinical study for PD-L1 positive NSCLC patients, the overall objective response rate (ORR) was 59%, and the disease control rate (DCR) was 97% [6][9]. Competitive Landscape - Compared to other PD-(L)1/VEGF dual antibodies, 707 is at a relatively advanced stage in clinical development, with only one competitor, AK112, having been approved for market [13][18]. - The combination of dual antibodies and antibody-drug conjugates (ADCs) is expected to become a new generation of tumor immunotherapy, with limited competition in the PD-(L)1 dual antibody space [2][18]. Financial Forecast - The company’s financial projections indicate steady revenue growth, with expected revenues of 9.004 billion, 10.123 billion, and 11.177 billion yuan for 2024-2026, respectively [21].
三生制药：业绩保持稳健增长，创新药临床快速推进-20250221